$3.870
+0.233 (+6.03%)收盘时
PSTV 资讯
PSTV 事件
Plus Therapeutics Collaborates with GTC to Integrate Genomic Testing Technology
Plus Therapeutics and Genomic Testing Cooperative announced a collaboration to integrate GTC's next-generation sequencing technology into the CNSide cerebrospinal fluid assay platform. The collaboration is expected to enable comprehensive DNA and RNA profiling across hundreds of clinically relevant biomarkers from a single CSF specimen, extending CNSide from guideline-recognized CTC enumeration into the guideline-recognized DNA and tumor-derived DNA analytic layer within one integrated platform.
Plus Therapeutics Rebrands to Cerenome, Nasdaq Ticker Changes to CNSY
Plus Therapeutics provided a business update. Notably, the company announces it is changing its company name from Plus Therapeutics to Cerenome and Nasdaq ticker to (CNSY), effective August 3. Furthermore, the company affirmed its anticipated 2026 milestones guidance, including commercial guidance around its CNSide Diagnostics business unit.
Plus Therapeutics Files $100M Mixed Securities Shelf
Plus Therapeutics files $100M mixed securities shelf
Plus Therapeutics Signs Strategic Partnership with Ephemeral Technologies
Plus Therapeutics announced that it has signed an agreement to enter into a strategic partnership with Ephemeral Technologies to deliver an AI execution platform for CNS oncology. The AI execution platform is designed to integrate, organize, and derive actionable intelligence from longitudinal therapeutic, diagnostic and bioinformatic data sets generated across Plus' CNS oncology technology programs.
Plus Therapeutics Q1 Revenue Exceeds Expectations at $1.03M
Reports Q1 revenue $1.03M, consensus $974,000. "Our team remains focused on our two highest-priority 2026 goals, CNSide commercial scale-up and REYOBIQ pivotal-trial readiness," said Marc Hedrick, Plus Therapeutics president and CEO. "We continue to add payers for CNSide, including a fourth national payer, expanding coverage to approximately 81 million covered lives, as well as receiving a unique PLA code for billing and successfully enrolling CNSide with Medicare. Concurrently, we secured FDA Orphan Drug Designation for REYOBIQ in pediatric malignant gliomas, while progressing on the ReSPECT-LM clinical trial. We enter the second quarter with the resources and focus to continue to deliver on our 2026 milestones."
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。